I think the point was stopping a P3 trial v a weak drug. That competition is building from competitors that may shortened the dosage from in some cases with Ibrutinib remaining lifetime v 6 months. That everything may be priced in unless they prove otherwise within their pipeline.
the mkt cap is now roughly 200 million. Also a share offering at 14. So the healthcare mkt could really drive future revenues with higher margins ANY thoughts????
" Still a buyer on every pullback :) MASSIVE GAINS " Zanger
where do you get the numbers of combining the merger? TB was not public co was it? So how many shares outstanding and so forth.... A 10 q???
the Baker Brs have been involved with IDRA for years. Yet they have invested even more since the stock seen the low.
I have 20 years experience in SCI research and I can see through your BS. Love the egotistical penny stock pumpers
I posted a remark about a chart pattern because others were posting patterns also. No big deal ! ! I hope you are less serious in general. But hey I didn't mention that is why I bought Mr.Stickler. Glad u did some general research .
breaking out. IDRA has been around a long time but they seem to be on to something again and have a plan to move the share price. long @ 2.62 and adding.
Sentiment: Strong Buy